A B S T R A C T
Background: Growth arrest specific 2-like protein 1 (GAS2L1) protein is a member of the GAS2 family of proteins, known to regulate apoptosis and cellular cytoskeleton reorganization in different cells. Recently we identified that Gas2l1 gene expression in podocytes is influenced by advanced glycation end product-bovine serum albumin(AGE-BSA). Methods: The study was performed employing cultured podocytes and diabetic (db/db) mice, a model of type 2 diabetes. Akbuminuria as wellas urinary neutrophil gelatinase-associated lipocalin (NGAL) excretion as measured with specific ELISAs. Gene expression was analysed via semiquantitative and realtime polymerase chain reaction. The protein levels were determined by western blotting and immunostaining. Results: We found that the Gas2l1a isoform is expressed in podocytes. Treatment with AGE-BSA induced Gas2l1a and Gas2 mRNA levels compared with controls incubated with non-glycated control BSA (Co-BSA). Moreover, application of the recombinant soluble receptor of AGEs (sRAGE), a competitor of cellular RAGE, reversed the AGE-BSA effect. Interestingly, AGE-BSA also increased the protein levels of GAS2L1a in a RAGE-dependent manner, but did not affect the GAS2 expression. Periodic acid-Schiff staining and albuminuria as well as urinary NGAL excretion revealed that db/db mice progressively developed diabetic nephropathy with renal accumulation of N e -carboxy-methyl-lysine (immunohistochemistry, western blots). Analyses of GAS2L1a and GAS2 proteins in diabetic mice revealed that both were significantly elevated relative to their non-diabetic littermates. In addition, GAS2L1a and GAS2 proteins positively correlated with the accumulation of AGEs in the blood plasma of diabetic mice and the administration of sRAGE in diabetic mice reduced the glomerular expression of both proteins. Conclusions: We show for the first time that the protein expression of GAS2L1a in vitro and in vivo is regulated by the AGE-RAGE axis. The suppression of AGE ligation with their RAGE in diabetic mice with progressive nephropathy reversed the GAS2L1a expression, thus suggesting a role of GAS2L1a in the development of diabetic disease, which needs to be further elucidated.
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I N T R O D U C T I O N
The family of the growth arrest specific (GAS) proteins contains six members, which are commonly upregulated in growtharrested fibroblasts and negatively regulated by serum or growth factors [1] . The most studied GAS proteins are GAS1, GAS2 and GAS6. It is known that overexpression of GAS1 inhibits the proliferation of different cell lines [2, 3] and tumour cell growth [4] . It has also been reported that GAS1 is involved in mouse embryonic [5] and kidney development [6] . GAS6 has been shown to induce mesangial hypertrophy in diabetic nephropathy [7, 8] . Yanagita et al. [9] demonstrated that GAS6 is induced in nephrotoxic nephritis and that Gas6 À/À mice displayed reduced mortality, proteinuria and glomerular injury.
GAS2 is involved in many cellular processes. It has been shown to interact with the microfilament system in fibroblasts and to act as a regulator protein in the cell cycle, particularly at the G 0 -G 1 transition of the cell cycle [10, 11] . It is also known to be involved in apoptosis [12] [13] [14] .
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Nephrol Dial Transplant (2017) 32: 641-653 doi: 10.1093/ndt/gfw313 Advance Access publication 16 September 2016 Cellular growth arrest, that is, the G 0 -phase of the cell cycle, is a temporary or permanent exit from the cell cycle, but cells keep their ability to regenerate. Terminal differentiated cells such as podocytes are in the G 0 phase [15, 16] . Podocytes are part of the glomerular filtration barrier. Via their characteristic multiple branched foot processes, adjacent podocytes form the so-called filtration slits. To maintain the filtration barrier, podocytes do not undergo the cell cycle [15, 16] . Under pathological conditions, such as in the diabetic milieu, podocytes re-enter the cell cycle (but cannot complete the cell division), mainly to compensate for the loss of adjacent podocytes [17, 18] . The consequences are cellular/podocyte hypertrophy, alterations in podocyte-glomerular basement membrane or podocyte-podocyte interactions and finally the loss of these cells, impairing glomerular filtration [16, 19] . One of the injuring factors in the pathophysiology of diabetic nephropathy is advanced glycation end products (AGEs) [20, 21] . Differential display analysis has demonstrated an increased expression of GAS2L1 (GAS2-like protein 1) in podocytes treated with advanced glycation end product-bovine serum albumin (AGE-BSA) [22] . GAS2L1 was first identified in 1996 as a homologue of GAS2 [23] , but there are very few studies analysing the GAS2L1 molecule. It is known to bind and crosslink microfilaments and microtubules in vivo and in vitro [24, 25] . In addition, Stroud et al. [25] demonstrated that GAS2L1 takes part in microtubule stability and its overall dynamic as well as guiding microtubules along actin stress fibres. To date there are no data addressing the function of GAS2L1 or GAS2 in diabetic disease or their potential role in differentiated podocytes. Thus we investigated the influence of AGEs on the expression of GAS2L1 and GAS2 in vitro in cultured immortalized podocytes and in vivo by exploring a murine model of type 2 diabetes.
M A T E R I A L S A N D M E T H O D S

Podocytes cell culture and treatments
Conditionally immortalized murine podocytes (a gift from Prof Peter Mundel, Massachusetts General Hospital, Charlestown, MA, USA) were cultured as described previously [26] . Briefly, the cells were grown for at least 2 weeks under permissive conditions (33 C) in RPMI 1640 medium (Invitrogen, Darmstadt, Germany) supplemented with recombinant mouse interferon-c (IFN-c; 10 IU/mL; Immunotools, Darmstadt, Germany) and 10% heat-inactivated foetal calf serum (FCS). Next, the cells were maintained at 37 C and cultivated in RPMI 1640 (Invitrogen) supplemented with 10% heat-inactivated FCS without IFN-c for 2 weeks, which induced podocyte differentiation. Differentiation of the podocytes was confirmed by detection of synaptopodin expression, a protein specific for differentiated podocytes [26] , by immunostaining using the goat anti-synaptopodin antibody (1:100; Santa Cruz Biotechnology, Heidelberg, Germany). For these analyses, differentiated podocytes (named further throughout the study shortly) were seeded at 70% confluence in RPMI 1640 medium (Invitrogen) supplemented with 10% heat-inactivated FCS. Podocytes were then incubated overnight in RPMI 1640 medium supplemented with 0.1% heat-inactivated FCS and afterwards stimulated with 5 mg/mL AGE-BSA and also with non-glycated Co-BSA for 24 h. AGE-BSA was prepared from albumin, bovine serum, fraction V, fatty-acid poor, endotoxinfree (Calbiochem, Darmstadt, Germany) as previously described [22, 27] . The glycation of BSA was characterized by determination of the N e -carboxy-methyl-lysine (CML) concentration in AGE-BSA and Co-BSA by CML ELISA (Cell Biolabs, San Diego, CA, USA). We detected that the CML concentration in AGE-BSA was 58-fold higher than measured in the control BSA (AGE-BSA 11.6 nmol/mg versus 0.2 nmol/mg protein in Co-BSA). The influence of the RAGE was assayed by incubation of cultured podocytes with recombinant soluble endotoxin-free His-RAGE (sRAGE) (Invigate, Jena, Germany). The sRAGE was dissolved in RPMI 1640 medium (Invitrogen) supplemented with 0.1% FCS and as appropriate 0.1 mg/mL sRAGE was added to the cells alone or in the presence of Co-BSA or AGE-BSA to sequester glycated BSA. sRAGE operates like a competitive inhibitor of the cell membrane bound RAGE.
Reverse transcription and real-time PCR
Total RNA was isolated from podocytes using the Qiagen RNAeasy kit (Hilden, Germany). Routinely, total RNA was reverse transcribed into cDNA by the use of reverse transcription system (Invitrogen). Semiquantitative PCR was performed on a T 0 . The relative expression ratio was quantified by the DDCT method [28] . For analysis of the full-length cDNA sequence of the isoform-specific expression of Gas2l1 the following primers were used: forward, 5 0 -CTGGGCATGGCGAACCCAGTGGCG-3 0 (common for both isoforms); Gas2l1a, reverse 5 0 -AAGCGAAAAGCAGCTCACA AACCCC-3 0 ; Gas2l1b, reverse 5 0 -GGTCCATCACATCGAA GAATCTGG-3 0 . All primers were purchased from Invitrogen.
Western blot analysis
Total protein was isolated from podocytes and from the cortices of whole mouse kidneys with complete Lysis-M buffer supplemented with protease inhibitors (both from Roche Diagnostics, Mannheim, Germany). Total protein was isolated from cortices of the podocytes from whole mouse kidneys with complete lysis-M buffer supplemented with protease inhibitors (both from Roche Diagnostics, Mannheim, Germany). Protein lysates were separated on 12% SDS-PAGE and western blot analyses were done as described elsewhere. For protein detection the following antibodies were used: goat anti-GAS2 (Santa Cruz Biotechnology, Heidelberg, Germany; 1:500), rabbit anti-GAS2L1 antibody that recognized GAS21a and GAS2L1b isoforms (1:500; Abcam, Cambridge) and mouse anti-vinculin (1:2000; Santa Cruz Biotechnology). The quantification of the protein expression was performed by ImageJ software. The GAS2L1a and GAS2 protein expressions were normalized to the expression of vinculin and are presented in percent and compared with the Co-BSA-treated cells.
Proteins were extracted from whole renal homogenates using the ProteoExtract Subcellular Proteome Extraction Kit (Calbiochem, Merck, Darmstadt, Germany). Fifty micrograms of protein lysate from the membrane fraction was loaded into each lane. SDS-PAGE and western blotting were performed as described elsewhere [19] . To assess the protein expression of CML, the membrane was further incubated overnight with a primary anti-CML antibody (Cell Biolabs) at a dilution of 1:100 in 5% BSA-tris-buffered saline with Tween (TBST) washed several times with TBST and incubated for 1 h with a horseradish peroxidase-conjugated goat anti-rabbit secondary antibody (1:2000; KPL, Gaithersburg, MD, USA). Equal loading was controlled by re-incubation with a monoclonal antibody against vinculin (Sigma-Aldrich, St. Louis, MO, USA). After intensive washing, the proteins were visualized with enhanced chemiluminescence detection reagent (Carl Roth & Co., Karlsruhe, Germany).
Immunofluorescent staining
For indirect immunofluorescence detection of proteins the podocytes were grown in chamber slides (Permanox; Thermo Scientific Nunc, Langenselbold, Germany) and appropriately treated. Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100. Slides were incubated with the follwoing primary antibodies goat anti-GAS2 (1:200; Santa Cruz Biotechnology) and then with rabbit anti-GAS2L1 (1:100; Abcam) followed by incubation with the secondary antibodies Alexa Fluor 568 donkey anti-goat and Cy3 goat anti-rabbit, both purchased from Invitrogen. Negative controls were performed using normal goat or rabbit IgG as an isotype control antibody (Santa Cruz Biotechnology). The slides were analysed on a computer-assisted Axioplan microscope with an Axiocam HRC digital camera and AxioVision 4.6 software (Zeiss, Jena, Germany). All images were captured using identical settings. Renal detection of GAS2L1, GAS2 and synaptopodin protein expression were analysed by indirect immunofluorescent staining performed on 2-mm paraffin kidney sections. After deparaffinization the sections were exposed to heat-mediated antigen retrieval in citrate buffer (pH 6.0). For double immunodetection, slides were incubated overnight at 4 C with the primary antibodies used in the following combinations: goat anti-GAS2 (1:50; Santa Cruz Biotechnology) and rabbit anti-synaptopodin (1:100; Sigma Aldrich, Darmstadt, Germany) or rabbit anti-GAS2L1 (1:100; Abcam) and goat anti-synaptopodin (1:100; Santa Cruz Biotechnology). After one more blocking step, the slides were incubated with the secondary antibody Alexa Fluor 568 donkey anti-goat or Cy3 goat anti-rabbit for 2 h in the dark, followed by incubation with Alexa Fluor 488 donkey anti-rabbit or Alexa Fluor 488 donkey anti-goat (1:500; all Invitrogen). To evaluate the glomerular protein expression, 15 glomeruli per mice were analysed using the AxioVision (release 4.6) software (Zeiss).
Immunohistochemical staining
Detection of the renal levels of CML was performed on 2-mm kidney paraffin sections by immunohistochemistry. The slides were exposed to 3% H 2 O 2 after antigen retrieval and afterwards blocked with RotiBlock (Carl Roth & Co.). Sections were incubated with the primary anti-CML antibody (1:200; Cell Biolabs) overnight at 4 C, followed by a 30-min incubation with ZytoChem Plus HRP Polymer anti-rabbit (Zytomed Systems, Berlin, Germany). The staining was visualized with the HRP substrate 3,3 0 -diaminobenzidine (DAB) (Vector Laboratories, Burlingame, CA, USA). Nuclei were counterstained with Mayer's haematoxylin (Carl Roth & Co.). Negative controls were performed using non-immune sera from the appropriate species. The staining was analysed using a semiquantitative scoring system, where 0 was no stain detected and 5 was intensive stain.
Animal experiments
The animal experiments were approved by the local Thuringia ethics committee. Mice were maintained in a 12-h light-dark cycle and were supplied with normal chow and water ad libitum. db/m and db/db mice (B6.Cg-mþ/þLepr db /J) (Bar Harbor, ME, USA) were used for the animal experiments. Diabetic db/db mice are characterized by a spontaneous homozygous mutation of the leptin receptor and are used as a model to study type 2 diabetes in rodents [29] . The mice were treated with sRAGE as described previously [30] . Briefly, 10-week-old mice were injected intraperitoneally (i.p.) with 20 mg/day endotoxin-free, recombinant soluble His-sRAGE (Invigate) with an equimolar concentration of mouse serum albumin (MSA) (Sigma Aldrich) for 14 consecutive days. After that the mice were sacrificed and the kidneys were paraffin-embedded or stored at À80 C for further analyses. Blood samples were also collected and stored at À80 C. Because of the high cost of sRAGE, this experiment was performed as a proof-of-concept experiment with a limited number of mice.
Diabetic db/db and non-diabetic db/m littermates at ages 6, 27 and 47 weeks were also used for analyses, but without sRAGE treatment. The mice were sacrificed at the appropriate age and the kidneys were extracted and paraffin-embedded for further studies.
Analysis of kidney morphology, albuminuria and urinary NGAL excretion
Kidney morphology was studied by periodic acid-Schiff (PAS) reaction on deparaffinized kidney sections using a PAS staining kit and sections were counterstained with Mayer's haematoxylin (both Carl Roth &Co.). Staining was analysed as described above using a semiquantitative scoring system where 0 was no, or little damage detected and 5 was intensive damage.
Albuminuria was determined by the albumin:creatinine ratio (ACR). Urinary albumin was measured from 6-to 27-week-old db/m and db/db mice by a mouse-specific albumin ELISA (Cell Trend, Luckenwalde, Germany) and urinary creatinine was measured using a colorimetric assay kit (Cayman Chemicals, Ann Arbor, MI, USA).
The Quantikine Mouse Lipocalin-2/NGAL Immunoassay ELISA from R&D Systems (Wiesbaden, Germany) was used according to the recommendations of the manufacturer to determine urinary NGAL concentrations.
The content of AGEs was analysed by measuring blood plasma levels of CML. CML concentration was detected using the CML ELISA assay (Cell Biolabs) according to the manufacturer's instructions and as previously described [30] . The concentrations of CML were calculated using the standard curve method and expressed in absolute terms (ng/mL).
Statistical analysis
All data are reported as mean 6 standard deviation (SD). Statistical analysis was performed using the statistical package SPSS for Windows version 11.0 (SPSS, Chicago, IL, USA). The data were analysed with the Kruskal-Wallis test followed by the Mann-Whitney U-test. Differences were considered significant for P< 0.05. The correlation between GAS2L1/GAS2 protein expression in kidney glomeruli of db/db mice and CML plasma concentration as well as the trend between CML glomerular levels and the expression of the GAS2L1a and GAS2 proteins in glomeruli were analysed by Spearman's rank correlation coefficient (q).
R E S U L T S
Gas2l1 and Gas2 are expressed in differentiated podocytes in vitro A differential display assay showed that the gene expression of Gas2l1 is regulated by AGEs in cultured differentiated podocytes [22] . There are two Gas2l1 isoforms present in cells, a shorter Gas2l1a and a longer Gas2l1b molecule [24] , but there are no data about its expression in renal cells. We tested which of the Gas2l1 isoforms is expressed in podocytes. Semiquantitative PCR analyses revealed that the Gas2l1a isoform was expressed in cultured podocytes ( Figure 1A and B). The primers used for an amplification of the full-length cDNA showed for the Gas2l1a gene, a PCR product of 1034 bp, as predicted, whereas for Gas2l1b only a short product that did not correspond to the full-length cDNA of Gas2l1b was detected, which is 2030 bp ( Figure 1B ). GAS2L1 belongs to the GAS2 family of proteins, thus we assessed the Gas2 gene expression as well. Gas2 is also expressed in differentiated podocytes ( Figure 1C) .
AGEs increased the expression of GAS2L1a in differentiated podocytes in vitro
To determine whether AGE-BSA modulates the Gas2l1a mRNA levels we exposed the podocytes to AGE-BSA, followed by Co-BSA. Real-time PCR analyses revealed that the application of AGE-BSA significantly enhanced Gas2l1a mRNA expression in podocytes (Figure 2A ). In agreement with this finding, western blot analysis demonstrated that AGE-BSA significantly increased the protein level of GAS2L1a in podocytes compared with Co-BSA ( Figure 2B ), indicating that the elevated protein expression was due to transcriptional changes. Moreover, the western blot showed that the shorter protein isoform GAS2L1a (37 kDa) was present but not the larger GAS2L1b (73 kDa) ( Figure 2B ).
AGEs signal to the cells via RAGE [31] . To estimate the role of RAGE in this process, the RAGE competitor sRAGE was added to the cells. The supplementation of sRAGE reduced the AGE-mediated augmentation of Gas2l1a mRNA ( Figure 2A ) and GAS2L1a protein expression ( Figure 2B ), whereas it did not affect the Co-BSA treatment (Figure 2A and B) . By applying immunofluorescent staining we studied the cellular distribution of GAS2L1a in podocytes treated with Co-BSA or AGE-BSA. We observed that GAS2L1a is located in speckle-like structures and is dispersed in the cell body of podocytes incubated with Co-BSA, and the addition of AGE-BSA to the cells significantly increased the GAS2L1a staining intensity and enriched the amount of the GAS2L1a-positive granules (shown with arrows in Figure 2C ). Small amounts of GAS2L1a protein were detected in the cell nucleus, but this did not change with AGE-BSA treatment of the podocytes.
Influence of AGEs on GAS2 expression in podocytes
GAS2L1 is a member of the GAS2 family. Therefore, we also investigated the Gas2 expression and found that, similar to Gas2l1a,its mRNA levels were increased in podocytes after AGE-BSA treatment compared with Co-BSA ( Figure 3A) . Interestingly, western blot analysis did not show significant differences between the Co-BSA-and AGE-BSA-treated cells but revealed a band of $25 kDa that had a lower molecular weight than the expected 37-kDa protein for GAS2 as described elsewhere [1] (Figure 3B ). The interference of RAGE signalling by sRAGE application also did not affect protein expression. We assessed the cellular localization of GAS2 and found a different distribution in podocytes compared with the GAS2L1a protein.
GAS2 protein was present in cell nuclei ( Figure 3C , arrows) and it showed membrane localization (marked with asterisk in Figure 3C ) in both Co-BSA-and AGE-BSA-stimulated podocytes. Thus GAS2 may play a role in the membrane ruffling in podocytes as previously reported for other cells [12] .
Treatment of diabetic mice with sRAGE prevented the AGE-induced changes in GAS2L1a and GAS2 glomerular protein expression
We further investigated the expressions of GAS2L1a and GAS2 in diabetic mice (db/db) and their non-diabetic littermates (db/m). These mice progressively developed typical morphological (glomerular sclerosis, tubulointerstitial fibrosis, see Figure 4A ) as well as functional (albuminuria Figure 4C , Ngal excretion Figure 4C ) features of diabetic nephropathy. Unfortunately, no urine samples from 47-week-old mice were obtained, but the notably increased structural renal damage ( Figure 4 ) clearly indicates progressive diabetic nephropathy. To further study the role of the AGE-RAGE axis in the modulation of GAS2L1a and GAS2 expression in the diabetic milieu we injected sRAGE i.p. in the db/db and control db/m mice or an equimolar concentration of MSA as a control.
Indirect immunofluorescent double staining with synaptopodin showed that the GAS2L1a protein ( Figure 5A ) was expressed in the glomeruli of diabetic and non-diabetic mice. Moreover, GAS2L1a glomerular expression was significantly increased in the podocytes of the diabetic mice compared with the nondiabetic littermates ( Figure 6B ). The podocytes were visualized Similar to the in vitro data from the cultured podocytes, sRAGE administration significantly diminished the GAS2L1a staining intensity in glomerular podocytes compared with the MSAtreated controls ( Figure 5A and B) . The investigation of GAS2 glomerular expression also depicted a significant elevation of GAS2 levels in the db/db mice compared with the db/m controls ( Figure 5C and D). The nuclear localization of GAS2 protein, observed in cultured podocytes, was also characteristic for glomerular cells as seen on the 'merge' images with DAPI nuclear counterstain ( Figure 5C ). Interestingly, it seems that only the expression of GAS2L1a was significantly increased in podocytes of the diabetic mice, whereas for GAS2 the 'merge' images with synaptopodin suggest that glomerular, but not necessarily podocyte-specific, expression was increased ( Figure 5C ). Closer inspection showed that the expression of GAS2 protein is mainly increased in the mesangial cells, a finding that needs to be further investigated (this analysis is limited by the lack of a suitable marker specific for mouse mesangial cells).
GAS2L1a protein expression in glomerular podocytes positively correlates with the accumulation of CML in blood plasma of diabetic mice
The serum and tissue concentrations of AGEs increase with the development of diabetic disease [32] . Thus, we tested whether the expression of GAS2L1a in glomerular podocytes of 6-, 27-and 47-week-old diabetic mice differs compared with older diabetic mice. Analyses of the GAS2L1a protein expression showed that its levels were significantly upregulated in the 27-and 47-week-old db/db mice compared to with the 6-weekold db/db mice ( Figure 6A and B) . Next, we assayed whether GAS2L1a protein levels correlate with AGE content. Next, we determined whether GAS2L1a protein levels correlate with AGE levels. We measured the age-dependent changes of CML concentrations in the blood plasma of db/db mice. CML is an AGE that is accumulated in the plasma of diabetic patients [33] and mice [30] . Our data revealed that CML plasma concentrations positively correlated with the GAS2L1a protein expression in diabetic mice (q ¼ 1) (Figure 6C ), suggesting that CML amounts could contribute to the increase in the GAS2L1a expression in type 2 diabetes.
GAS2 protein expression in diabetic glomeruli positively correlates with the accumulation of CML in blood plasma of diabetic mice
We also investigated whether the GAS2 protein is changed in older diabetic mice. Our data showed that GAS2 staining intensity increased significantly in 47-week-old db/db mice compared with 6-week-old mice ( Figure 7A and B) . We also found that the GAS2 expression in diabetic glomeruli was 
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increased with elevated CML plasma concentrations in db/db mice ( Figure 7C ). Spearman's correlation between CML concentrations and the expression of GAS2 protein in diabetic glomeruli showed a positive correlation (q ¼ 1) ( Figure 8C ).
CML-modified products in kidney glomeruli and whole renal lysates were elevated in aged diabetic mice
We next investigated whether the levels of CML-modified proteins changed in diabetic mice depending on their age. Immunohistochemistry showed significantly increased CML levels in the kidneys of the 27-and 47-week-old db/db mice compared with the 6-week-old mice, whereas there was only a slight difference in CML between the 27-and 47-week old mice ( Figure 8A and B) . We also compared trends between the expressions of GAS2L1a and GAS2 proteins in the diabetic glomeruli and levels of glomerular CML. Spearman's rank correlation coefficient (q) showed that there was a positive relationship between the increased GAS2L1a/CML ( Figure 8C ) and GAS2/ CML ( Figure 8D ) amounts in the glomeruli of the diabetic mice.
Western blots of total renal homogenates revealed a progressive increase in CML content in db/db mice with age ( Figure 9 ).
D I S C U S S I O N
Podocytes, with their unique cellular architecture and numerous foot processes, are important for maintaining glomerular filtration. Foot processes of adjacent cells form the so-called filtration slits [15, 16] . Injury of these terminal differentiated cells under diabetic conditions damages the glomerular filtration There are no significant differences in protein expression between Co-BSA and AGE-BSA. In both treatments GAS2 displays membrane as well as nuclear localization. The nuclear GAS2 protein (red) co-localizes with DAPI nuclear counterstain (blue). The purple staining in the merge image reflects the nuclear co-localization of GAS2. Arrows designate the nuclear staining in a single cell. The membrane GAS2 stain is shown with an asterisk on the images. Representative images of the GAS2 stain and the merge images are shown. Original magnification Â400. Bars correspond to 20 mm; n ¼ 4. [17, 19] . Diabetes-related generation and accumulation of AGEs due to prolonged hyperglycaemia affect the expression of many genes, thus contributing to the development of diabetic nephropathy [34] . There are a number of studies demonstrating the impact of AGEs on podocytes [21, 30, 35, 36] . Previous investigations in our laboratory found that AGEs affect the expression of various genes in podocytes [22, 30, 36] . Injury to these terminal differentiated cells caused by diabetic conditions damages the glomerular filtration barrier [17, 19] . The diabetesrelated generation and accumulation of AGEs due to prolonged hyperglycaemia affects the expression of many genes, thereby contributing to the development of diabetic nephropathy [34] . Initial differential display approaches have shown that the gene expression of the growth arrest-specific molecule Gas2l1 is altered when cultured podocytes were incubated with AGE-BSA [22] . There are fewer studies on the molecule GAS2L1. Until now it is only known to bind and crosslink microfilaments and microtubules [24, 25] . Zucman-Rossi et al. [23] identified at least two isoforms of GAS2L1 in the foetal brain, a protein with a deduced molecular mass of 37 kDa termed GAS2L1a and a protein of $73 kDa termed GAS2L1b [24] . Goriounov et al. [24] detected the highest levels of Gas2l1 mRNA in mice heart, testes and liver, and lower amounts in the kidney, brain and lungs, where the Gas2l1b isoform dominated. The authors observed no GAS2L1a protein in mice tissue specific to mRNA expression. In contrast to these studies that detected GAS2L1b, FIGURE 4: Periodic acid-Schiff (PAS) staining of db/m and db/db mice at different ages. db/db mice progressively developed typical features of diabetic nephropathy with aging, such as basement membrane thickening, glomerulosclerosis, interstitial atrophy and fibrosis. Although not surprisingly, db/m mice also showed with increasing age some other conditions such as glomerulosclerosis, these morphological alterations were significantly more common in diabetic db/db mice. ***P < 0.001 versus 6 weeks, ## P < 0.01 versus age-matched db/m, # P < 0.05 versus age matched db/m, n ¼ 6; at least 15 sections from both kidneys (left and right) were analysed.
we found that both mRNA and protein of the GAS2L1a isoform are expressed in cultured podocytes, but we did not find the GAS21b isoform either as mRNA or as a protein in the podocytes. In part, these discrepancies could be related to the different antibodies used in the studies.
Treatment of podocytes with AGE-BSA demonstrated a significantly increased GAS2L1a expression both in mRNA and as a protein, indicating that this increase was a result of transcriptional alteration. In agreement with this observation, the immunofluorescence studies also showed an accumulation of GAS2L1a in AGE-BSA-treated podocytes and an accumulation in granule-like formations, which was different from previous reports, depicting GAS2L1a mostly in actin stress fibres [24, 25] . These differences could also suggest a somewhat distinct FIGURE 5: Influence of sRAGE on the glomerular expression of GAS2L1a and GAS2 protein in db/db mice. (A) Immunofluorescence staining of GAS2L1a in kidney paraffin sections of db/m and db/db mice treated with sRAGE or MSA. The GAS2L1a expression in podocytes is visualized by double staining with synaptopodin on the the merge images. The yellow staining in the merge images reflects the colocalization of GAS2L1a with synaptopodin (arrows). The non-specific tubular stain of synaptopodin in some of the merge images is marked by asterisks. Representative images of the GAS2L1a stain and the merge images are shown. Original magnification Â400. Bars equal to 20 mm; red, GAS2L1 a; green, synaptopodin. (B) Evaluation of GAS2L1a staining intensity. The glomerular GAS2L1a expression in db/db-MSA mice was significantly increased compared with db/m-MSA animals. The administration of sRAGE in mice significantly decreased the protein expression in db/db-sRAGE mice relative with db/db-MSA animals. The glomerular protein expression was quantified from at least 15 glomeruli per kidney section and is graphically presented relative to db/m MSA treatment. MSA treatment, n ¼ 3 mice; sRAGE treatment, n ¼ 2 mice. ***P< 0.001, *P< 0.05 versus db/m, ## P< 0.01 versus MSA. (C) Immunofluorescence staining of GAS2. The analysis demonstrated a significantly increased glomerular GAS2 expression in the db/db MSA mice compared with the non-diabetic db/m controls. The administration of sRAGE significantly prevented the enhancement of GAS2 protein expression in diabetic animals. The podocytes are visualized by synaptopodin stain as shown by arrows in the merge images. The non-specific tubular stain of synaptopodin in some of the merge images is marked by asterisks. Representative images of the GAS2 stain and the merge images are shown. Original magnification Â400; red, GAS2; green, synaptopodin. (D) Evaluation of GAS2 staining intensity. GAS2 expression is enhanced in db/db-MSA mice compared with db/m-MSA animals. The application of sRAGE in mice significantly decreased the protein expression in db/db-sRAGE mice relative to db/db-MSA animals. The glomerular protein expression was quantified from at least 15 glomeruli per kidney section obtained from both kidneys (there was no difference between the kidneys) and is graphically presented relative to db/m MSA treatment. MSA treatment, n ¼ 3 mice; sRAGE treatment, n ¼ 2 mice. ***P< 0.001 versus db/m, ### P< 0.001 versus MSA. Correlation of GAS2 protein expression with CML content in blood plasma of aged diabetic mice. (A) Changes in GAS2 protein expression in podocytes of diabetic mice with age. The immunofluorescence analysis showed increased GAS2 glomerular protein staining in aged diabetic mice. The podocyte-specific synaptopodin staining is shown by arrows on the merge images, while the non-specific tubular stain of synaptopodin is shown with asterisks. Representative images of the GAS2 stain and the merge images are shown. Original magnification Â400. Bars correspond to 20 mm; red, GAS2; green, synaptopodin. (B) The quantification of glomerular GAS2 expression revealed a significantly increased GAS2 protein expression in 47-weeks-old db/db mice compared with 6-weeks-old diabetic animals. The staining intensity was normalized to 6-weekold db/db animals. n ¼ 4 for each group except 47 weeks, where n ¼ 2 mice.*P< 0.05 versus 6 weeks. (C) The GAS2 glomerular expression correlates positively with the CML blood plasma content in diabetic mice. Spearman's correlation analysis demonstrated a positive relationship between the increased glomerular protein expression of GAS2 in diabetic mice and the elevated CML blood plasma content of these mice. q ¼ 1; n ¼ 4 for each group except 47 weeks, where n ¼ 2 mice. It is well known that podocytes have a welldeveloped cytoskeleton apparatus, but we did not observe GAS2L1a in stress fibre-like formations. Thus, the exact role of GAS2L1a in damage to podocytes and in diabetic nephropathy is yet to be clarified. On the other hand, interference with the binding of AGE-BSA to RAGE by application of sRAGE reduced AGE-BSA-mediated enhancement of GAS2L1a expression. Furthermore, our results also showed that the protein levels of GAS2L1a in glomeruli and glomerular podocytes positively correlated with the accumulation of CML, a wellknown AGE occurring in diabetic mice [30] and humans [33, 37] . In addition, our data linked the elevated GAS2L1a protein in db/db mice, a well-documented model of type 2 diabetes, to AGE accumulation; blockage of the RAGE signalling by administration of sRAGE reduced the glomerular as well as the FIGURE 9: (A, B)Western blot of whole kidney lysates incubated with an antibody against CML. The renal CML content of db/m as well as db/db mice progressively increased with age CML content; however, compared with non-diabetic db/m animals the CML content was higher in lysates from db/db mice. This blot is representative for three independent experiments with qualitatively similar findings. Western blot of whole kidney lysates incubated with an antibody against CML. (C). In addition, Plasma CML concentrations were significantly increased in 27 weeks db/db mice comparted to age matched db/m (###P<0.005) as well as 6 weeks old db/db mice (***P<0.005), n=8). *P<0.05 versus db/db, **P<0.01 versus db/db, 'P>0.05 versus 6 weeks db/m. Our morphological (PAS staining) as well as functional (albuminuria, urinary NGAL excretion) data revealed that over time, diabetic db/db mice developed typical features of diabetic nephropathy, demonstrating that these mice are a suitable model to study GAS2L1a in vivo. It is interesting that GAS2L1a was observed mostly in adult diabetic mice and it was expressed only at low levels in young diabetic mice. This may suggest a role for the GAS2L1a protein more specific to a later stage in diabetic injury, such as during development of diabetic nephropathy, than to some early effects in kidney injury. Therefore, similarl to the GAS6 protein that was previously reported to have a function in glomerular mesangial cell hypertrophy [8] , GAS2L1a could play a role in the hypertrophy of podocytes in diabetes. Further studies are currently under way to test this intriguing hypothesis.
Since GAS2L1a is a homologue of GAS2, we also tested the expression of GAS2 in podocytes. We detected both GAS2 mRNA and protein in cultured podocytes. Our data showed that AGE-BSA increased Gas2 mRNA expression in podocytes, in an AGE-BSA/RAGE-dependent manner, as addition of sRAGE to the cells reduced the mRNA levels found in AGE-BSA-treated podocytes. On the other hand, neither AGE-BSA nor sRAGE was able to influence the protein expression of GAS2. Interestingly, western blot analysis of cultured podocytes revealed a protein band with a molecular weight of 25 kDa, much smaller than the expected size of 37 kDa, which is the predicted molecular weight of the protein, based on the protein sequence. This may be related to a post-transcriptional modification of GAS2 associated with a caspase protease cleavage, as shown previously in studies of Brancolini et al. [12] . However, in the case of differentiated podocytes, this finding is presumably due to the differentiated state of the cells and is not due to apoptotic events in the cells, as we also found this size of the protein in cells cultured in medium supplemented with 10% FCS (data not shown). It is possible that the increased glomerular expression of GAS2 in db/db mice is instead caused by increased mesangial cell expression versus stimulated podocyte expression. Nevertheless, our studies showed that GAS2 protein accumulation is increased in the glomeruli of aged diabetic mice as well as positively correlated to the CML levels in blood plasma of db/db mice. Administration of sRAGE also reduced GAS2 glomerular (likely mesangial) expression in db/db mice compared with the MSA treatment.
In summary, our data demonstrated for the first time that AGEs induce an increase of GAS2L1a protein expression in cultured podocytes, whereas they have no influence on GAS2, but affected the mRNA expression of Gas2. Future studies are certainly necessary to analyse whether these changes in the expression of GAS2L1a are relevant for the injury of podocytes in diabetic nephropathy and which molecular mechanisms are involved. Moreover, it will be interesting to test the impact of AGEs on the expression of GAS2 in mesangial cells. Nagai et al. [7] have shown that GAS6 expression is elevated in diabetic glomeruli. In addition, they demonstrated that the enhanced GAS6 levels induce glomerular hypertrophy by activating the Akt/ mTOR pathway [7, 8, 38] , which has been associated with an induction of p27 Kip1 (a cell cycle inhibitor protein) and Akt [7, 8, 38] . p27
Kip1 is already known to be involved in the hypertrophy of podocytes as well as mesangial cells in diabetic nephropathy [21, 36, 39] . The link between the expressions of GAS2L1a and GAS2 and increased p27
Kip1 protein expression due to the cell cycle arrest of podocytes is currently under investigation by our group.
GAS2L1 is known to interact with microfilaments and microtubules in vivo. In this context it was demonstrated that these molecules increase the stability of microtubules [24, 25] . Therefore it may be possible that the elevated expression of GAS2L1a and/or GAS2 plays a role in podocyte cytoskeleton structures, especially microfilaments and microtubules, and that the treatment of podocytes with AGEs changes this colocalization.
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